Latest News - Johnson & Johnson
Top Corporates Hub
Johnson & Johnson
J&J to build $1bn US CGT manufacturing site in Pennsylvania
19.02.2026 12:02
The Pennsylvania site is one of four US-based manufacturing sites J&J plans to build over the next four years.
Johnson & Johnson to Invest More Than $1 Billion in Pennsylvania Cell Therapy Factory
18.02.2026 15:44
The facility is part of the company’s plans to invest $55 billion in U.S. manufacturing, research and development and technology through early 2029.
Johnson & Johnson Expands U.S. Footprint with more than $1 Billion Investment in Next Generation Cell Therapy Manufacturing Facility in Pennsylvania
18.02.2026 15:15
NEW BRUNSWICK, N.J., February 18, 2026--Johnson & Johnson (NYSE: JNJ) (the "Company"), healthcare’s leading, most comprehensive innovation powerhouse, today announced a more than $1 billion investment in a next generation cell therapy manufacturing facility in Montgomery County, Pennsylvania. This new facility will further expand the Company’s U.S. manufacturing capacity as it advances its industry leading portfolio and pipeline of transformational medicines for cancer, immune-mediated and neuro
Verizon vs Johnson & Johnson: Which Dividend Hike Winner Is the Better Buy?
18.02.2026 14:15
Verizon (NYSE: VZ) and Johnson & Johnson (NYSE: JNJ) both rewarded shareholders with dividend increases this quarter, but their paths to sustaining those payouts look very different. Verizon raised its quarterly dividend to $0.69 per share, marking its 19th consecutive annual raise. Johnson & Johnson lifted its quarterly payout to $1.30 per share, extending a ... Verizon vs Johnson & Johnson: Which Dividend Hike Winner Is the Better Buy?
Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It
18.02.2026 14:00
Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Is Kenvue (KVUE) Attractively Priced After Spin Off From Johnson & Johnson?
18.02.2026 12:09
If you are wondering whether Kenvue's current share price lines up with its underlying value, you are not alone, this article breaks down what the market might be pricing in. The stock last closed at US$18.41, with returns of 0.5% over 7 days, 7.0% over 30 days, 6.3% year to date and a 12.7% decline over the past year, which gives a mixed picture of recent sentiment. Recent headlines have focused on Kenvue's position as a standalone consumer health company following its separation from...
Johnson & Johnson Announce Breakthrough Therapy Designation From FDA For RYBREVANT In Non-Small Cell Lung Cancer
18.02.2026 08:36
Trellus Health Extends Johnson & Johnson Collaboration Through Mid-2026 On Same Economic Terms After Achieving Key Engagement And Satisfaction Metrics
18.02.2026 03:46
This State Has More Millionaires Per Capita Than Any Other
18.02.2026 02:21
There are many ways to describe America. Some might call it a veritable patchwork of diverse cultures and social strata. That’s a fancy way of saying that prosperity is concentrated in some U.S. states more than in others. As a result, a handful of America’s 50 states have more millionaires than others. By the process ... This State Has More Millionaires Per Capita Than Any Other
Dividend Income: Lanny's December 2025 Summary
17.02.2026 06:23
Dividend Income is the fruit from the labor of investing your money in the stock market. In December, we (my wife and I) received a dividend income total of $8,010.54. Read more here.
AbbVie: Dominating Immunology While Building Oncology Upside
17.02.2026 01:11
The total net revenues of AbbVie's Rinvoq and Skyrizi were about $25.87 billion in 2025, up 46.2% from 2024. Read why ABBV stock is a Buy.
What to Expect From These Drug/Biotech Players This Earnings Season?
16.02.2026 19:11
Let's take a closer look at what awaits Bausch Health, Amicus Therapeutics, BioMarin Pharmaceutical, Insmed and Madrigal Pharmaceuticals as they prepare to report quarterly results this week.
J&J's MedTech Shows Strong Growth in 2025: Will 2026 be Better?
16.02.2026 14:55
JNJ's MedTech unit grows in 2025 on cardiovascular strength; with new launches, can 2026 bring faster growth?
H.C. Wainwright Bullish on Genmab A/S (GMAB) on Robust Sales for DARZALEX
13.02.2026 10:19
Genmab A/S (NASDAQ:GMAB) is one of the High Growth International Stocks to Buy Now. On January 28, H.C. Wainwright reiterated a Buy rating on Genmab A/S (NASDAQ:GMAB) and maintained a $39 price target. The rating follows robust net sales of DARZALEX in 2025. The company on January 21 reported a significant increase in net sales […]
Johnson And Johnson Cardiac Data Fuels Fresh Look At Valuation Upside
12.02.2026 02:15
Johnson & Johnson (NYSE:JNJ) presented pilot-phase data for its OMNYPULSE and VARIPULSE atrial fibrillation platforms at the 31st Annual AF Symposium. The company reported industry first safety and effectiveness outcomes for these pulsed field ablation technologies. The data suggest potential for redefining minimally invasive electrophysiology procedures in cardiac care. For you as an investor, this update sits inside Johnson & Johnson’s broader medical technology push, where cardiac care...
[Latest] Global Cell Therapy Raw Materials Market Size/Share Worth USD 29.3 Billion by 2035 at a 18.9% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
11.02.2026 08:30
[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Cell Therapy Raw Materials Market size & share revenue was valued at approximately USD 5.2 Billion in 2025 and is expected to reach USD 6.1 Billion in 2026 and is expected to reach around USD 29.3 Billion by 2035, at a CAGR of 18.9% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Thermo Fisher Scientifi
How Recent Analyst Shifts Are Rewriting The Story For Johnson & Johnson (NYSE:JNJ)
11.02.2026 00:17
What Is Driving the New Fair Value Estimate for Johnson & Johnson? The fair value estimate for Johnson & Johnson has shifted from about US$224.09 to roughly US$231.25 per share, and the revenue growth assumption has moved from about 5.81% to roughly 6.04%, with a small change in the discount rate from 6.96% to 6.98% to reflect a slightly different view of risk. Recent Street research has tilted more positive, with several firms raising price targets and one new initiation that calls the stock...
Here's What Will Drive AbbVie's Top-line Growth in 2026
10.02.2026 13:32
ABBV sees 2026 revenues rising to $67B as Rinvoq and Skyrizi drive growth, with neuroscience gains offsetting Humira erosion and oncology headwinds.
Where is Genmab A/S (GMAB) Headed According to Wall Street?
10.02.2026 11:41
Genmab A/S (NASDAQ:GMAB) is one of the best healthcare stocks under $50 to invest in. Genmab A/S (NASDAQ:GMAB) announced on January 21 that the worldwide net trade sales of DARZALEX, including sales of the subcutaneous product (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO® in the U.S.), as reported by J&J, came up to $14.351 billion […]